510(k) Report

510(k) · Cleared

Cleared

Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast Flucytosine

K133952510(k) TraditionalCleared Aug 19, 2014239-day reviewClass II21 CFR 866.1640

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

bioMerieux, Inc. · NGZ Susceptibility Test Plate, Antifungal

Cleared on Aug 19, 2014 as substantially equivalent to K092454 (bioMerieux, Inc., 2010) after a 239-day review. Its family tree reaches back 1 generation to 2010. 5 later devices descend from it.

Decided
Aug 19, 2014
Review
239 days
Class
Class II
Product code
NGZ
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K092454 (2010). 5 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2016: 2 descendants cleared2022: 1 descendant cleared2018: 1 descendant cleared2024: 1 descendant clearedK092454 · Vitek 2 Yeast Voriconazole · bioMerieux, Inc. · 20102010201520202025
Descendants, by generation 1 generation forward: 2 descendants2 generations forward: 2 descendants3 generations forward: 1 descendant K092454 · Vitek 2 Yeast Voriconazole · bioMerieux, Inc. · 20100
  1. Root · 1 generation backK092454 Vitek 2 Yeast VoriconazolebioMerieux, Inc. · 2010
  2. This deviceK133952 Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast FlucytosinebioMerieux, Inc. · 2014
  3. Descendant · cites it directly · 2 of its ownK151817 VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc. · 2016
  4. Descendant · 2 generations on · 1 of its ownK213899 VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS…bioMerieux, Inc. · 2022
  5. Descendant · cites it directly · 1 of its ownK151923 VITEK 2 AST-Yeast Micafungin (0.06-8 mcg/mL)bioMerieux, Inc. · 2016
  6. Descendant · 3 generations on · 0 of its ownK232963 VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024
  7. Descendant · 2 generations on · 0 of its ownK181368 VITEK 2 AST-YS Micafungin (<=0.06 - =>8 µg/mL)bioMerieux, Inc. · 2018

Most influential descendants

Showing 5 of 5 · See all
  • K151817VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc. · 2016 · cites it directly2descendants
  • K213899VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS Caspofungin (<=0.125…bioMerieux, Inc. · 2022 · 2 generations on1descendant
  • K151923VITEK 2 AST-Yeast Micafungin (0.06-8 mcg/mL)bioMerieux, Inc. · 2016 · cites it directly1descendant
  • K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024 · 3 generations on0descendants
  • K181368VITEK 2 AST-YS Micafungin (<=0.06 - =>8 µg/mL)bioMerieux, Inc. · 2018 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K092454Vitek 2 Yeast VoriconazolebioMerieux, Inc.2010—
0 (this device)K133952Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast FlucytosinebioMerieux, Inc.2014—
+1K151817VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc.2016—
+2K213899VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS…bioMerieux, Inc.2022—
+1K151923VITEK 2 AST-Yeast Micafungin (0.06-8 mcg/mL)bioMerieux, Inc.2016—
+3K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc.2024—
+2K181368VITEK 2 AST-YS Micafungin (<=0.06 - =>8 µg/mL)bioMerieux, Inc.2018—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201620
201810
202210
202410
FIG. 1 — Lineage of K133952, 2010–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NGZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NGZ device

  1. #1 K232963 VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >=…score 8.4 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K092454Vitek 2 Yeast Voriconazole
Summary page 5
…VITEK 2 AST-YS Flucytosine ® C. Predicate Device: VITEK 2 AST-YS Voriconazole (K092454). D. 510(k) Summary: ® VITEK 2 Yeast Flucytosine is designed for antimicrobial susceptibility testing of Candida…
bioMerieux, Inc.2010—

Also cleared against K092454: 1 other device →

What descends from it? (5)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K151817VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc.20162
K151923VITEK 2 AST-Yeast Micafungin (0.06-8 mcg/mL)bioMerieux, Inc.20161

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K151817 (bioMerieux, Inc., 2016) has gone furthest, with 2 descendants of its own.
  • 1 other device also cites its predicate K092454.

How does its category compare?

All NGZ devices

NGZ Susceptibility Test Plate, Antifungal: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · NGZ

1in 2025

2009: 32010: 22014: 32016: 22018: 12021: 12023: 32024: 22025: 1
2007high 3 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NGZ

204in 2023

2009: 326 days median2014: 232 days median2023: 204 days median
2007high 326 (2009) · low 204 (2023)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NGZ

2in 2022

2022: 2
2007high 2 (2022) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NGZ

1in 2024

2011: 12014: 12015: 12016: 92017: 162018: 102021: 82022: 32023: 32024: 1
2007high 16 (2017) · low 0 (2007)2025

MAUDE reports naming product code NGZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
2009332600
20102—00
20110—01
20120—00
20130—00
2014323201
20150—01
20162—09
20170—016
20181—010
20190—00
20200—00
20211—08
20220—23
2023320403
20242—01
20251—00
20260—0—

What is it indicated for?

VITEK® 2 Yeast Flucytosine is designed for antimicrobial susceptibility testing of clinically significant yeast species and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Yeast Flucytosine is a quantitative test. Flucytosine has been shown to be active against most isolates of the microorganisms listed below, according to the FDA…

Read the full statement (154 words)

VITEK® 2 Yeast Flucytosine is designed for antimicrobial susceptibility testing of clinically significant yeast species and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Yeast Flucytosine is a quantitative test. Flucytosine has been shown to be active against most isolates of the microorganisms listed below, according to the FDA label for this antifungal.

Active in vitro and in clinical infections

Candida albicans

The following in vitro data are available, but their clinical significance is unknown.

Candida dubliniensis

Candida glabrata

Candida guilliermondii

Candida lusitaniae

Candida parapsilosis

Candida tropicalis

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.

Indications for use as stated in the FDA summary.

Also cleared against K092454

1 other device cites the same predicate.

  • K133817Vitek 2 Ast - Yeast FluconazolebioMerieux, Inc. · 2014

More from bioMerieux, Inc.

281 FDA decisions under this applicant name. See the company

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystembioMerieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025
  • K234012Vitek Compact ProbioMerieux, Inc. · 2025

Recent decisions in NGZ

The NGZ category page

  • K243738The Sensititre YeastOne Susceptibility System with Micafungin in the dilution range of 0.008-16 µg/mLThermo Fisher Scientific · 2025
  • K232967VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)bioMerieux, Inc. · 2024
  • K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024
  • K231433The Sensititre YeastOne Susceptibility System with Rezafungin in the dilution range of 0.008-8ug/mLThermo Fisher Scientific · 2023
  • K221198Sensititre YeastOne Susceptibility System with Fluconazole in the dilution range of 0.12-128ug/mLThermo Fisher Scientific · 2023

https://510kreport.com/device/K133952 · printed Nov 6, 2026

Cite this page

510(k) Report. “K133952: Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast Flucytosine.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K133952

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026